Navigation Links
arGEN-X raises EUR 5 Million from PMV in Extension of EUR 32.5 Million Series B
Date:11/4/2013

BREDA, The Netherlands and GHENT, Belgium, November 4, 2013 /PRNewswire/ --

Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, towards clinical development

arGEN-X, a clinical stage human therapeutic antibody company, has raised EUR 5 million ($6.8 million) as an extension of its series B financing round from the Flemish investment company PMV as a new investor. arGEN-X' series B round, which had its first close in December 2011, now totals EUR 32.5 million ($44 million).

The proceeds will be used to accelerate the Company's ARGX-113 preclinical program towards clinical development. ARGX-113 is a novel therapeutic approach to virtually any antibody-mediated pathology. ARGX-113 exploits arGEN-X' proprietary ABDEG™ technology which clears and degrades systemic disease-causing autoantibodies. ARGX-113 is applicable to most autoimmune diseases (e.g. rheumatoid arthritis, systemic lupus erythmatosus), including unmet orphan indications (e.g. myasthenia gravis, immune thrombocytopenic purpura, Kawasaki disease). ARGX-113 has also a potential use in other therapies where anti-drug antibodies eventually reduce or neutralize the effect of therapeutic proteins.

PMV is an independent investment company that invests in companies contributing to sustainable economic development in the region of Flanders. PMV has a EUR 900m portfolio of assets under management. Life sciences represent a particular focus area for PMV's corporate investments. At arGEN-X, PMV joins a blue-chip group of international investors including OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Omnes Capital, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.

Tim Van Hauwermeiren, CEO of arGEN-X, commented: "The ARGX-113 program has made rapid and exciting progress
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
5. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
6. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
9. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
10. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
11. Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NORWALK, Conn. , Oct. 22, 2014  Recently ... (GERD) have bolstered the already substantial database of evidence. ... and adoption of Stretta therapy for sufferers ... of clinical evidence supporting Stretta therapy as ... coverage policies that make Stretta therapy available to nearly ...
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... Valeritas, Inc., a leader in simple, disposable ... 2 diabetes, announced today that it has received a ... was presented October 16 th at Cardinal,s annual ... . The Cardinal Health Supply Chain ... metrics specifically targeted at the importance of developing collaborative ...
Breaking Medicine Technology:Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... , MAPLE GROVE, Minn., Dec. 3 Upsher-Smith ... plan for central nervous system (CNS) diseases with USL255 (extended ... epilepsy. USL255 is being developed with Upsher-Smith,s proprietary formulation technology ... 2010 for the adjunctive treatment of epilepsy patients with partial ...
... , HARRISBURG, Pa., Dec. 3 ... processing company build a new cold storage facility and ... at least 20 jobs, Governor Edward G. Rendell announced ... more than $2.9 million for three projects. The investments, ...
Cached Medicine Technology:Upsher-Smith Announces Milestone in Development of CNS Strategy 2Governor Rendell: New State Investments Bear Fruit in Adams County; Help Pharmaceutical Company Expand in Philadelphia 2
(Date:10/22/2014)... PA (PRWEB) October 22, 2014 Richard ... as an industry leader with over 25 years experience. ... team leader in the areas related to EDI, B2B ... Carlson is an Editorial Advisory Board member for Pharmaceutical ... Educator. Blue Fin Group is a management and ...
(Date:10/22/2014)... News) -- Two sisters in high school have developed ... and Medha Krishen use electronic stethoscopes, which electronically amplify ... breathing patterns or heartbeats. Ilina, a senior at ... find a way to detect early lung damage in ... stethoscope, Ilina recorded one breath cycle each from 16 ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, ... tightened guidelines for health workers treating Ebola patients, now requiring ... a respirator at all times. The U.S. Centers for ... after two Dallas nurses contracted Ebola while caring for the ... Thomas Eric Duncan. Nina Pham is currently being treated for ...
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 T.E.N., ... relationship-marketing firm, announced today that William H. Murray, ... the 2014 ISE® Luminary Leadership Award winner. Presented ... achievements of an outstanding leader and industry practitioner ... contributions in advancing the information security industry. , ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... (TSX: RBM, OTCBB: RPBIF) reported that it recorded ... $13,901,041 or ($0.12) per share,for the year ended ... of December 31, 2007 it had approximately $8.2 ... the Company,s financial results for,the year ended December ...
... China,Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN ) ... the research, development, manufacture,and marketing of pharmaceutical, nutritional ... China ("PRC"), today announced it will,conduct a conference ... 2, 2008, to,discuss the Company,s financial results for ...
... NMHC,s Stockholders Accept ... SXC,s ... -,SXC Health Solutions Corp. ("SXC") (Nasdaq: SXCI ; TSX: SXC) ... jointly announced,today that, pursuant to their previously announced merger agreement, SXC ...
... finds uncertainty about risks and benefits of mastectomies or ... half the women diagnosed with early-stage breast cancer clearly ... a breast-conserving lumpectomy plus radiation, even after they have ... , If the woman is black or Hispanic, the ...
... CNS Response,Inc. (OTC Bulletin Board: CNSO) ... roll out referenced-EEG(R) (rEEG(R)) availability with an,undisclosed, ... enables psychiatrists under the management of the ... to treat their most,therapy-challenged patients suffering any ...
... 31 LCA-Vision Inc. (Nasdaq:,LCAV), a leading provider ... announced the opening of its 76th LasikPlus(R) vision,center ... fourth,LasikPlus(R) vision center opened this year, and the ... opened a LasikPlus(R) vision,center in Paramus in April ...
Cached Medicine News:Health News:Response Biomedical Corporation Reports 2007 Financial Results 2Health News:Response Biomedical Corporation Reports 2007 Financial Results 3Health News:Response Biomedical Corporation Reports 2007 Financial Results 4Health News:Response Biomedical Corporation Reports 2007 Financial Results 5Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 3Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 2Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 3Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 4Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 5Health News:Many Women Unclear About Breast Cancer Treatments 2Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 2Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 3Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 4Health News:LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey 2
... E-Gel® 96 and E-Gel® 48 ... E-Base™ electrophoresis bases, which combine the ... device. , The mother E-Base™ power ... can be connected directly to an ...
... Turn routine agarose gel electrophoresis into ... 96 system. This bufferless, pre-cast system is ... preparations, restriction digests, and more. Fully automated, ... the E-Gel 96 system makes your high-throughput ...
... System provides a compact format to rapidly ... PCR products and synthetic oligonucleotides, while using ... Horizontal Unit has gel bed dimensions of ... bed is UV transparent. Adjustable height Combs ...
... for very fast and clear separation of DNA restriction ... to cast, run, and perform Southern or Northern blotting ... electrophoresis tank and cover, 1 x Gel Maker Stand ... x MT-T02 (50 x 60 mm tray), 1 x ...
Medicine Products: